A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibroids

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

357

Participants

Timeline

Start Date

September 10, 2022

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions

Uterine Fibroids With Menorrhagia

Interventions

DRUG

SHR7280 tablets

SHR7280 tablets 300mg for 12 weeks

DRUG

SHR7280 tablets

SHR7280 tablets 400mg for 12 weeks

DRUG

PlaceboSHR7280 tablets blank preparation

Placebo group: SHR7280 tablets blank preparation for 12 weeks

Trial Locations (1)

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY